Pekka Tammela

DSA is a Finnish health care technology company, whose novel BreathPass™ analyzing device and COVID-19 test revolutionize large-scale community-based COVID-19 screening with a low-cost, non-invasive, and highly accurate COVID test. DSA BreathPass™ COVID-19 test sets a new standard for efficiently screening large groups with industry-leading “real-time” test results. DSA is an innovative, growth-oriented, and globally minded company. We are passionate about creating an intelligent, AI-powered technology that can scale to address the world’s growing demand for real-time screening. We are driven to provide a disruptive COVID screening solution that helps individuals, families, and communities return to normal at work, school, and play. Our main product, DSA BreathPass™ is a handheld device intended for rapid screening of large numbers of people to provide presumptive negative results of COVID-19 infection. Inside the device there is an array of nano-sensors to detect molecules of biological origin, known as volatile organic compounds (VOC), as signs of infection stemming from the biomarkers known to be produced by the metabolic processes caused by the SARS-CoV-2 virus. DSA will continue to investigate opportunities to widen the analysis of exhaled breath as an indicator for severe diseases. With our state-of-the-art DSA BreathPassTM analyzing device we feel it is possible to come up with solutions for the early indication of developing lung cancer, colon cancers, pneumonia to name a few. We actively look at research and development partners who would like to participate in the future of medical science. Let us know what would be your angle of interest. Please take a look at our website for more details and datasheets.

Revenio is a leading company in the global market for ophthalmological devices and software solutions. Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand. iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for the diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). iCare Solutions provide digital clinical tools that drive greater efficiency and enhance quality in eye care. In 2021, the Group’s net sales totaled EUR 78.8 million, with an operating profit of EUR 22.1 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V. Revenio on kansainvälisillä markkinoilla toimiva oftalmologisten laitteiden ja ohjelmistoratkaisujen globaali kärkiyhtiö. Revenio-konsernin silmän diagnostiikkaratkaisuihin kuuluvat iCare-brändin alla silmänpaineen mittauslaitteet (tonometrit), silmänpohjan kuvantamislaitteet, perimetrit ja kliiniset ohjelmistot. iCare on silmädiagnostiikan luotettu kumppani, joka tarjoaa lääkäreille nopeita, helppokäyttöisiä ja luotettavia työkaluja glaukooman, diabeettisen retinopatian ja silmänpohjan rappeuman diagnosointiin. iCare Solutions -kokonaisratkaisut tarjoavat digitaalisia kliinisiä työkaluja, jotka lisäävät tehokkuutta ja parantavat näönhoidon laatua. Revenio-konsernin liikevaihto vuonna 2021 oli 78,8 miljoonaa euroa ja liiketulos 22,1 miljoonaa euroa. Revenio Group Oyj:n osake on listattu Nasdaq Helsinki Oy:ssä kaupankäyntitunnuksella REG1V.

DSA is a Finnish health care technology company, whose novel BreathPass™ analyzing device and COVID-19 test revolutionize large-scale community-based COVID-19 screening with a low-cost, non-invasive, and highly accurate COVID test. DSA BreathPass™ COVID-19 test sets a new standard for efficiently screening large groups with industry-leading “real-time” test results. DSA is an innovative, growth-oriented, and globally minded company. We are passionate about creating an intelligent, AI-powered technology that can scale to address the world’s growing demand for real-time screening. We are driven to provide a disruptive COVID screening solution that helps individuals, families, and communities return to normal at work, school, and play. Our main product, DSA BreathPass™ is a handheld device intended for rapid screening of large numbers of people to provide presumptive negative results of COVID-19 infection. Inside the device there is an array of nano-sensors to detect molecules of biological origin, known as volatile organic compounds (VOC), as signs of infection stemming from the biomarkers known to be produced by the metabolic processes caused by the SARS-CoV-2 virus. DSA will continue to investigate opportunities to widen the analysis of exhaled breath as an indicator for severe diseases. With our state-of-the-art DSA BreathPassTM analyzing device we feel it is possible to come up with solutions for the early indication of developing lung cancer, colon cancers, pneumonia to name a few. We actively look at research and development partners who would like to participate in the future of medical science. Let us know what would be your angle of interest. Please take a look at our website for more details and datasheets.

PJ Maa Partners on yrityskauppoihin, erilaisiin omistus- ja rahoitusjärjestelyihin sekä yrityskehittämiseen erikoistunut asiantuntijayritys. www.pjmaa.fi PJ Maa Partners is specialised in M&As, corporate finance and business development. www.pjmaa.fi

Oivaltava hallitus on yrityksen kilpailutekijä. Yhdessä valtakunnallisesti toimivan Hallituspartnerit-verkoston kanssa rakennamme Suomea, jossa on menestyvä ja kasvava pk-yrityskenttä. Hallituspartnerit-verkoston tarkoitus on elinkeinoelämän kilpailukyvyn vahvistaminen erityisesti pk-yritysten hallitustyöskentelyä kehittämällä.